Does Rallies show Form 4 insider transactions for STXS?

Yes. Rallies tracks STXS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is STXS research on Rallies investment advice?

No. Rallies provides research, data, and educational context for STXS. It does not provide personalized investment advice.

STXS (Stereotaxis, Inc. Common Stock) Stock Analysis - Insider Trades

Stereotaxis, Inc. Common Stock (STXS) is a publicly traded Healthcare sector company. As of May 21, 2026, STXS trades at $1.85 with a market cap of $173.97M and a P/E ratio of -7.65. STXS moved +6.94% today. Year to date, STXS is -21.61%; over the trailing twelve months it is -11.48%. Its 52-week range spans $1.54 to $3.59. Analyst consensus is strong buy with an average price target of $4.13. Rallies surfaces STXS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading STXS stock inside the company?

Recent STXS insider activity includes Isaac Paul J bought 10.00K, Isaac Paul J bought 20.00K, Isaac Paul J bought 38.00K, Isaac Paul J bought 1.49K, and Isaac Paul J bought 23.30K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

STXS Key Metrics

Key financial metrics for STXS
Metric	Value
Price	$1.85
Market Cap	$173.97M
P/E Ratio	-7.65
EPS	$-0.24
Dividend Yield	0.00%
52-Week High	$3.59
52-Week Low	$1.54
Volume	0
Avg Volume	0
Revenue (TTM)	$-681.00K
Net Income	$-21.68M
Gross Margin	-2467.11%

Recent STXS Insider Trades

Isaac Paul J bought 10.00K (~$21.80K) on Nov 17, 2025.
Isaac Paul J bought 20.00K (~$44.80K) on Nov 14, 2025.
Isaac Paul J bought 38.00K (~$68.78K) on Mar 10, 2025.
Isaac Paul J bought 1.49K (~$2.67K) on Mar 7, 2025.
Isaac Paul J bought 23.30K (~$42.17K) on Mar 6, 2025.

Latest STXS News

Stereotaxis Secures Approval for Next-Gen System and Reports Year-Over-Year Revenue Growth — May 13, 2026
Stereotaxis Reports $6.3M Q1 Revenue, Secures FDA Approvals and Robocath Acquisition — May 12, 2026
Stereotaxis Begins First U.S. MAGiC Procedures Following FDA PMA Approval — Apr 22, 2026
Stereotaxis Secures FDA Clearance for 55” 4K Synchrony System, Targets $3M Revenue — Apr 6, 2026
Stereotaxis Projects $3M Synchrony Revenue, Readies MAGiC PFA Launch in Europe — Mar 10, 2026

STXS Analyst Consensus

4 analysts cover STXS: 0 strong buy, 4 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $4.13.

Common questions about STXS

Who is trading STXS stock inside the company?: Recent STXS insider activity includes Isaac Paul J bought 10.00K, Isaac Paul J bought 20.00K, Isaac Paul J bought 38.00K, Isaac Paul J bought 1.49K, and Isaac Paul J bought 23.30K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for STXS?: Yes. Rallies tracks STXS insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is STXS research on Rallies investment advice?: No. Rallies provides research, data, and educational context for STXS. It does not provide personalized investment advice.